Dietary fat clearance in type V hyperlipoproteinaemia secondary to a rare variant of human apolipoprotein E: The apolipoprotein E3 (Arg 136 → Ser)

British Journal of Nutrition

Volumn 83, Issue 6, 2000, Pages 615-622

  Vialettes, Bernard ^a   Reynier, Pascal ^b   Atlan Gepner, Catherine ^a   Mekki, Nadia ^c   Lesluyes Mazzochi, Laurence ^a   Luc, Gérard ^d   Lairon, Denis ^c   Malthiery, Yves ^b  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c INSERM   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E3; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; FAMILIAL DISEASE; FAT INTAKE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 5; HYPERTRIGLYCERIDEMIA; LOW FAT DIET; MALE; POINT MUTATION;

EID: 0034081980     PISSN: 00071145     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0007114500000787     Document Type: Article

References (57)

1. Bard JM, Parra HJ, Douste-Blazy P & Fruchart JC (1990) Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant on lipoprotein particles defined by their apolipoprotein compositions. Metabolism 39, 269-273.
2. Björkegren J, Hamsten A, Milne RW & Karpe F (1997) Alteration of VLDL composition during alimentary lipemia. Journal of Lipid Research 38, 301-314.
3. Boerwinkle E, Brown S, Richey Sharett A, Heiss G & Patsch W (1994) Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. American Journal of Human Genetics 54, 341-360.
4. Brenninkmeijer BJ, Stuyt PMJ, Demacker M, Stalenhoef AFH & Van't Laar A (1987) Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype. Journal of Lipid Research 28, 361-370.
5. Brown AJ & Roberts DCK (1991) The effect of fasting triglyceride and concentration and apolipoprotein E polymorphism on post-prandial lipemia. Arteriosclerosis Thrombosis 11, 1737-1744.
6. Civeira F, Povoci M, Cenarro A, Vilella E, Gonzales J, Garcia-Otin AL & Ordovas JM (1996) Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis 127, 273-282.
7. Cohn JS, Johnson EJ, Millar HS, Cohn SD, Milne RW, Marcel YL, Russel RM & Schaefer EJ (1993) Contribution of apo B-48 and apo B-100 triglyceride-rich lipoprotein (TRL) to postprandial increases in plasma concentration of TRL triglycerides and retinyl esters. Journal of Lipid Research 34, 2033-2039.
8. Das HK, McPherson J, Bruns GAP, Karathanasis SK & Breslow JL (1985) Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. Journal of Biological Chemistry 260, 6240-6247.
9. Dubois C, Armand M, Azaiss-Baesco V, Portugal H, Pauli AM, Bernard PM, Latge C, Lafont H, Borel P & Lairon D (1994) Effects of moderate amounts of emulsified dietary fat on post-prandial lipemia and lipoproteins in normolipidemic adults. American Journal of Clinical Nutrition 60, 374-382.
10. Falko JM, Schonfeld G, Witltum JL, Kolar J & Weidman SW (1979) Effects of oestrogen therapy on apolipoprotein E in type III hyperlipoproteinemia. Metabolism 28, 1171-1177.
11. Feussner G, Albanese M & Mann WA (1996) Apolipoprotein E2 (Arg 136 → Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinemia. European Journal of Clinical Investigation 26, 13-23.
12. Ghiselli G, Schaefer EJ, Gascon P & Brewer HB Jr (1981) Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 214, 1239-1241.
13. Groot PHE, Van Stiphout WAHJ, Krauss XH, Jansen H, Van Tol A, Van Ramshorst E, Chin-On S, Hofman A, Cresswell SR & Havekes L (1991) Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arteriosclerosis Thrombosis 11, 653-662.
14. Havekes L, de Wit E, Leuven JG, Klasen E, Utermann G, Weber W & Beisigel U (1986) Apolipoprotein E3-Leiden: a new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Human Genetics 73, 157-163.
15. Havel RJ, Chao YS, Windier EE, Kotite L & Guo LSS (1980) Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of familial dysbetalipoproteinemia. Proceedings of National Academy of Sciences (USA) 77, 4349-4353.
16. Hegele RA, Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJ & Connelly PW (1993) Hepatic lipase deficiency. Clinical, biochemical and molecular genetic characteristics. Arteriosclerosis Thrombosis 13, 720-728.
17. Hixson JE & Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. Journal of Lipid Research 31, 545-554.
18. Hozumi Y, Kawano M, Saito T & Miyata M (1998) Relation between apolipoprotein phenotype and the changes in lipids during tamoxifen treatment. Endocrinology Journal 45, 255-259.
19. Karpe F, Steiner G, Uffelman K, Olivecrona T & Hamsten A (1994) Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106, 83-97.
20. Kosykh VA, Novikov DK, Trakht IN, Podrez EA, Victorov AV, Repin VS & Smirnov VN (1991) Effect of chylomicron remnants on cholesterol metabolism in cultured rabbit hepatocytes: very low density lipoprotein and bile acid production. Lipids 26, 799-805.
21. Kushwaha RS, Hazzard WR, Gagne C, Chait A & Albers JJ (1977) Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogens. Annals of Internal Medicine 87, 517-525.
22. Lalazar A, Weisgraber KH, Rall SC, Giladj H, Innerarity TL, Levanon AZ, Boyles JK, Amit B, Gorecki M, Mahley RW & Vogel T (1988) Site-specific mutagenesis of human apolipo-protein E. Journal of Biological Chemistry 263, 3542-3545.
23. 145 → Cys). Homozygoty for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. Journal of Biological Chemistry 266, 10479-10484.
24. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
25. Mann WA, Gregg RE Sprecher DL & Brewer HB (1989) Apolipoprotein E-1 Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochimica Biophysica Acta 1005, 239-244.
26. Martz W, Cezanne S & Gross W (1991) Phenotyping of apolipo-protein E by immunoblotting in immobilized pH gradients. Electrophoresis 12, 59-63.
27. Mekki N, Christofilis MA, Charbonnier M, Atlan-Gepner C, Defoort C. Juhel C, Borel P, Portugal H, Pauli AM, Vialettes B & Lairon D (1999) Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipo-proteins in adult women. Journal of Clinical Endocrinology and Metabolism 84, 184-191.
28. Miller DB, Hegele RA, Wolfe BM & Huff MW (1995) Identification, molecular characterization and cellular studies of an apolipoprotein E mutant (E1) in three unrelated families with hyperlipidemia. Journal of Clinical Endocrinology and Metabolism 80, 807-813.
29. Minnich A, Weisgraber KH, Newhouse Y, Doug LM, Fortin LJ, Tremblay M & Davignon J (1995) Identification and characterization of a novel apolipoprotein E variant apolipoprotein E3 (Arg 136 → His): association with mild dyslipidemia and double pre-beta very low density lipoproteins. Journal of Lipid Research 36, 57-66.
30. Moriyama K, Sasaki J, Takada G, Arakawa F, Matsunaga A, Ito Y & Arakawa K (1996) Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg 224 → Glu) in a hyperlipidemic patient with xanthomatosis. Biochimica Biophysica Acta 1301, 185-190.
31. Nilsson-Ehle P & Schotz MC (1976) A stable radioactive substrate emulsion for assay of lipoprotein lipase. Journal of Lipid Research 17, 536-541.
32. Okubo M, Aoyama Y, Harada K, Fukawa M, Toukada T, Mokuno H, Yamada N & Murase T (1998) A novel apolipoprotein E2 variant E2 Toranomon (Q 187 E) identified in a type III hyperlipoproteinemic patient with coronary atherosclerosis. Atherosclerosis 140, 187-190.
33. Ordovas JM, Litwack-Klein L, Wilson PWF, Schaefer MM & Schaefer EJ (1987) Apolipoprotein E isoforms phenotyping methodology and population frequency with identification of apo E1 and apo E5 isoforms. Journal of Lipid Research 28, 371-380.
34. Papamandjaris AA, MacDougall DE & Jones PJ (1998) Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications. Life Sciences 62, 1203-1215.
35. Parlier G, Thomas G, Bereziat G, Fontaine JL & Girardet JP (1997) Relation of apolipoprotein E polymorphism to lipid metabolism in obese children. Pediatric Research 41, 682-685.
36. Patsch JR, Miesenbock G, Hopferwieser T, Mühlberger V, Knapp E, Kay Dunn J, Gotto AM & Patsch W (1992) Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arteriosclerosis Thrombosis 12, 1336-1345.
37. Pocovi M, Cenarro A, Civeira F, Myers RH, Casao E, Esteban M &Ordovas JM ( 1996) Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg 136 → Ser) variant in multigenerational pedigree studies. Atherosclerosis 122, 33-46.
38. Rall SC, Weisgraber KH, Innerarity TL, Berot TP & Mahley RW (1983) Identification of a new structural variant of human apolipoprotein E, E2 (Lys 146-Gln) in a type III hyperlipoproteinemic subject with the E3/E2 phenotype. Journal of Clinical Investigation 72, 1288-1297.
39. Rall SC, Weisgraber KH & Mahley RW (1982a) Human apolipoprotein E. The complete amino acid sequence. Proceedings of National Academy of Science (USA) 79, 4696-4700.
40. Rall SC, Weisgraber KH & Mahley RW (1982b) Human apolipoprotein E. The complete amino acid sequence. Journal of Biological Chemistry-257, 4171-4178.
41. Reznik Y, Pousse P, Herrou M, Morello R, Mahoudeau J, Drosdowsky MA & Fradin S (1996) Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism. Metabolism 45, 63-71.
42. Richard P, de Zulueta MP, Beneler I, De Gennes JL, Cassaigne A & Iron A (1995) Identification of a new apoliprotein E variant (E2 Arg 142 → Leu) in type III hyperlipidemia. Atherosclerosis 112, 19-28.
43. Rosseneu M & Labeur C (1995) Physiological significance of apolipoprotein mutants. FASEB 9, 768-776.
44. Sijbrands EJ, Westendorp RG, Hoffer MJ, Frants RR, Meinders AE, Souveriijn JH, Gevers Leuven JA, Van der Laarse A, Havekes LM & Smelt AH (1996) Effect of lipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Atherosclerosis 126, 197-205.
45. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramian S, Baron D, Branson J, Morgan J & Roy P (1987) Chylomicrons and chylomicron remnants in coronary artery disease. Atherosclerosis 65, 181-189.
46. Srivasta RA, Srivasta N, Averna M, Lin RC, Korach KS, Lubahn DB & Schonfeld G (1997) Estrogen up-regulates apolipoprotein E (ApoE) gene expressions by increasing ApoE mRNA in the translating pool via the estrogen receptor alpha-mediated pathway. Journal of Biological Chemistry 272, 33360-33365.
47. Tozuka M, Yamauchi K, Hidaka H, Nakabayashi T, Okumara N & Katsuyama T (1997) Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma. Annals Clinical Laboratory Science 27, 351-357.
48. Walden CC & Hegele RA (1994) Apoprotein E in hyperlipidemia. Annals of Internal Medicine 120, 1026-1036.
49. Walden CC, Huff MW, Leiter LA, Connelly PW & Hegele RA (1994) Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping. Journal of Clinical Endocrinology and Metabolism 78, 699-704.
50. Wardell MR, Brennan SO, Janus ED, Fraser R & Carrell RW ( 1987) Apolipoprotein E2-Christchurch (136 Arg → Ser). Journal of Clinical Investigation 80, 483-490.
51. Weintraub G, Eisenberg S & Breslow JL (1987) Dietary fat clearance in normal subjects is regulated by genetic variations in apolipoprotein E. Journal of Clinical Investigation 80, 1571-1577.
52. Weisgraber H, Rall SC, Innerarity TL Mahley RW, Kuusi T & Ehnholm C (1984) A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein El. Journal of Clinical Investigation 73, 1024-1033.
53. Weisgraber KH, Innerarity TL & Mahley RW (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cystein-arginine interchange at a single site. Journal of Biological Chemistry 257, 2518-2521.
54. Wenham PR, McDowell IFW, Hodges VM, McEnemy J, O'Kane MJ, Davies RJH, Nicholls DP, Trimble ER &Blundell G (1993) Rare apolipoprotein E variant identified in a patient with type III hyperlipidemia. Atherosclerosis 99, 261-271.
55. Wilson C, Wardell MR, Weisgraber KH, Mahley RW & Agard DA (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252, 1817-1822.
56. Zhao SP, Van den Maagdenberg AM, Vroom TF, Van't Hooft FM, Gevers Leuven JA, Havekes LM, Frants R, Van der Laarse A & Smelt AH (1994) Lipoprotein profiles in a family with 2 mutants of apolipoprotein E: possible association with hypertriglyceridemia but not with dysbetalipoproteinemia. Clinical Science 86, 323-329.
57. Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60, 473-485.